Discontinuation report GARDASIL
| Report ID | 92342 |
| Drug Identification Number | 02283190 |
| Brand name | GARDASIL |
| Common or Proper name | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] - Suspension for Injection |
| Company Name | MERCK CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN |
| Strength(s) | 20MCG 40MCG 40MCG 20MCG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAMUSCULAR |
| Packaging size | 1 Dose |
| ATC code | J07BM |
| ATC description | VIRAL VACCINES |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2019-08-22 |
| Remaining supply date | 2018-12-04 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
| Company contact information | 1-800-567-2594 medinfocanada@merck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2019-08-23 | French | Compare |
| v1 | 2019-08-23 | English | Compare |
Showing 1 to 2 of 2